HIV Epidemic Profile in Russia and Preparing for Clinical Trials of the First Russian HIV Vaccine 'VICHREPOL'

摘要

HIV vaccines must generate neutralizing antibodies and T-helper immune response. To be broadly protective vaccine must comprise conserve antigens. Candidate anti HIV vaccine VICHREPOL based on recombinant protein rec(24-41) conjugated with immunomodulator polyoxidonium (PO) was prepared. Recombinant antigen comprises gag- and env-coded proteins (HTV1 p24 + fragment of gp41), conserve between HIV1 subtypes. PO represents novel potent safe immunomodulator approved for use in humans. Pre-clinical studies demonstrated immunogenicity and safety of candidate vaccine VICHREPOL with built-in adjuvant PO, the data were confirmed by RF Regulatory Authority. RF Ministry of Health approval of clinical trials Phase I pending. Basing on HIV epidemic profile in Russia, work with a drug user cohort is being prepared.